Suite 506, Level 5 50 Clarence
Street, Sydney NSW 2000,
Australia

hello@breathelifesciences.com

+61 2 9078 8180

14 September 2026

ANGUS WALKER APPOINTED AS ALTERNATE DIRECTOR TO EDWARD MYER

BLS Pharmaceuticals Limited (ASX: BLS) ("BLS" or "the Company") advises that Edward Myer, Non-Executive Director, has appointed Angus Walker as his alternate director. The Board has approved the appointment which is effective 14 September 2026.

As alternate director, Mr Walker will be able to attend and participate in Board meetings in Mr Myer's place when required.

Angus Walker is Chief Investment Officer of MWP Partners, a Hong Kong–based investment management firm which he co-founded with Edward Myer. At MWP, he leads the firm's investment strategies, with a focus on building alternative, high-conviction portfolios for global clients. He is also involved in the firm's direct balance sheet investments across private markets, with a focus on technology, healthcare and longevity, as well as distressed assets.

Prior to MWP, Angus was a Partner at IMS Digital Ventures, overseeing investments and strategy across healthcare, artificial intelligence, cybersecurity and fintech. He previously spent eight years as a Senior Analyst at EFM Asset Management, focused on global equities, and earlier worked at the Commonwealth Bank on digital banking and international strategy across Sub-Saharan Africa and Asia.

Non-Executive Chairman Anthony Ho commented:

"We are pleased to welcome Angus to the Board in his capacity as alternate director to Edward. His extensive investment experience across global equities, private markets, healthcare and technology will bring additional perspective to the Board as BLS continues to grow its international pharmaceutical platform."

Approved by the Board of BLS Pharmaceuticals Limited for release to the ASX.

For further information, please contact:

BLS Pharmaceuticals Limited

Anthony Ho
Non-Executive Chairman
tony@blspharma.com

NWR Communications

Melissa Tempra
Media & Investor Relations
melissa@nwrcommunications.com.au

About BLS Pharmaceuticals Limited

BLS Pharmaceuticals Limited (ASX:BLS) is an Australian pharmaceutical company focused on the manufacture, development and commercialisation of regulated therapeutic products and active pharmaceutical ingredients. Through its wholly owned subsidiary, Breathe Life Sciences, the Company operates a GMP-licensed manufacturing, import, export and distribution platform spanning medicinal cannabis, psychedelic medicines and other controlled pharmaceutical products.

BLS maintains operations across Australia, Europe, the United Kingdom and Japan, supplying pharmaceutical products and manufacturing services to regulated international markets through a growing network of commercial partners.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (BLS) is a wholly owned subsidiary of BLS Pharmaceuticals Limited and a GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances, including medicinal cannabis, psilocybin and MDMA.

Established in 2018, BLS has developed an international pharmaceutical manufacturing and distribution platform with operations across Australia, Japan, Scotland (UK) and Europe. The business specialises in final dose-form manufacturing, pharmaceutical distribution, contract manufacturing, international supply and the development of regulated therapeutic products.

BLS sources pharmaceutical raw materials and active pharmaceutical ingredients from a global supplier network and manufactures products for both its own brands and third-party customers. The Company owns the Dr Watson® brand portfolio across multiple international markets and supplies pharmaceutical products, active pharmaceutical ingredients and manufacturing services to customers globally.

In addition to its medicinal cannabis operations, BLS holds licences and capabilities supporting the manufacture, import, export and distribution of a range of regulated pharmaceutical products, positioning the business to participate in emerging therapeutic markets, including psychedelic medicines.

Corporate: **blspharma.com**

Australia: **bls.com.au**

International: **breathelifesciences.com**